Veru Reports First Patient Enrollment in the P-IIb Study of Enobosarm Plus Semaglutide for High Quality Weight Loss
Shots:
- The P-IIb study assesses the safety & efficacy of enobosarm (3mg, 6mg) or PBO to treat conserving muscle & augment fat loss among patients (n=~90) with sarcopenic obesity or overweight patients (>60yrs.) administered with Wegovy. Topline data is anticipated in Q4’24
- The 1EP is total lean body mass difference while the 2EPs are changes in total body fat mass & physical function at 16wks.
- After dose-finding part, the patients will enter into P-IIb extension study under which GLP-1 RA will be discontinued & enobosarm will be administered for another 12wks. to assess the ability of sustaining muscle mass and preventing fat & weight gain post GLP-1 RA discontinuation. Topline results are anticipated in Q2’25
Ref: Veru | Image: Veru
Related News:- Valeo Pharma Enters into a Commercial Services Agreement with Veru for Sabizabulin to Treat COVID-19 in Canada
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
